tegafur/uracil

After receiving tegafur-uracil (UFT) plus leucovorin in combination with bevacizumab for rectal cancer, he developed exertional dyspnea. DI-ILD associated with UFT is rare, and to the best of our knowledge, no previous reports have described an HP pattern on imaging. We therefore report this case with a review of the relevant literature.

The patient had previously received adjuvant oral tegafur-uracil for 2 years without any hematologic toxicity...Treatment with cyclosporine led to gradual hematologic improvement and transfusion independence. This is a rare case of osimertinib-induced aplastic anemia occurring after curative-intent surgery for NSCLC, in contrast to previously published reports that mainly involved patients with advanced or metastatic disease. Clinicians should be aware of this rare but life-threatening complication and closely monitor peripheral blood counts during treatment, particularly within the first 2-8 months after treatment initiation.

P3, N=10, Terminated, National Health Research Institutes, Taiwan | N=147 --> 10 | Enrolling by invitation --> Terminated; Recruiting progress behind expectation

Adjuvant UFT improves OS and RFS in EGFR wild-type pStage IA3-IIA lung adenocarcinoma, particularly in patients with high-risk pathological features. In contrast, UFT is ineffective in EGFR mutation-positive cases, highlighting the need for refined adjuvant treatment strategies tailored to EGFR status and tumor biology in early-stage lung adenocarcinoma with pathological N0 (pN0).

In pathologic stage I (>2 cm) lung adenocarcinomas with EGFR mutation, the survival benefit of adjuvant UFT was not observed.

While it is difficult to expect chemotherapy to be effective based on Ki67, PgR expression is low, so oral administration of tegafur-uracil (covered by insurance) was added instead of endocrine therapy alone... Of the total 82 patients (median age 54 [33-78] years), 10 patients (12%, median RS 25 [0-32]) received standard infusion chemotherapy including anthracycline/taxane, and 72 patients (88%, RS 15 [0-29]) omitted infusion chemotherapy. Of the 82 cases, 57 cases (70%, RS16 [0-32]) were POTENT eligible, and of the 72 cases in which infusion chemotherapy was omitted, 48 cases (59%, RS14 [1-27]) were eligible. After the results of the POTENT study were published, there were 4 cases (4.9%, RS18 [12-27]) that were POTENT eligible in which infusion chemotherapy was omitted but S-1 was used in combination.

UFT administration can improve the prognosis of EGFR mutation-negative LUAD but not EGFR mutation-positive LUAD. Thus, clinical trials of adjuvant-targeted therapy for EGFR mutation-positive stage IB LUAD should also be conducted in Japan.

Cortactin has a significantly impact in HPC patients. UFUR maintenance provided survival benefits in patients with cortactin (+) after adjuvant CRT.

To our knowledge, this is the first case report on metastatic esophageal cancer from signet-ring cell carcinoma of the cecum. Esophagoscopy showed multiple longitudinal submucosal tumors, which is similar to an endoscopic finding of intramural metastasis from primary esophageal cancer. We consider that the multiple longitudinal submucosal tumors are a notable feature of our case. When metastatic esophageal cancer is suspected, clinicians, endoscopists, and pathologists should consider signet-ring cell carcinoma of the colon as one of potential primary lesions. This consideration could lead the specialists to appropriate examinations and treatments, thereby improving clinical outcomes in patients with the metastasis.

adjuvant chemotherapy for completely resected p-stage IA (>2 cm) and stage IB non-small-cell lung cancer showed no benefit for recommendation for elderly patients; considering the risk of adverse events, we do not recommend adjuvant chemotherapy for elderly patients.

This study indicates that combining neoadjuvant LHRH antagonists and UFT followed by RARP may improve oncological outcomes in patients with high-risk PCa.

A defense mechanism against reactive oxygen species has been reported as a mechanism causing recurrence of CD44v9-positive gastric cancer. Consequently, CD44v9-positive gastric cancer grows in metastatic organs, repeatedly self-renews, and proliferates to form recurrent lesions. In the present case, the degree of CD44v9 staining in recurrent lesions was suggested to be related to the recurrence time.